Galectin Therapeutic (GALT): Congress and insider trades

Who in Congress and inside the company traded GALT, when each filing appeared, and what buying after each one would have earned against the S&P 500.

Key Facts

  • Galectin Therapeutic (GALT) is a listed stock on NASDAQ.
  • Insiders filed 0 open market buys worth $0 and 7 sells worth $522K, the latest filed 2026-07-16 (16 July 2026).
  • Data as of 2026-09-29 (29 September 2026).
Congress buys 0 0 members
Congress sells 0
Insider buys 0 $0
Insider sells 7 $522K
Congress buys vs S&P, 90d n/a 0 scored buys
Insider buys vs S&P, 90d n/a 0 scored buys

Insider trades in GALT

as of 2026-07-16
Open market insider trades in GALT, newest first.
FiledInsiderTypeSharesPriceValue90 day vs S&P
16 Jul 2026 Jamil Khurram sell 16,250 $5.13 $83.3K n/a
30 Jun 2026 Jamil Khurram sell 4,570 $5.00 $22.9K n/a
30 Jun 2026 Shlevin Harold H. sell 22,268 $5.04 $112K n/a
30 Jun 2026 Shlevin Harold H. sell 7,732 $5.00 $38.7K n/a
30 Jun 2026 Jamil Khurram sell 47,467 $5.04 $239K n/a
25 Jun 2026 Jamil Khurram sell 7,557 $3.14 $23.7K n/a
28 May 2026 Jamil Khurram sell 568 $3.10 $1.8K n/a

Frequently asked questions

Who has bought GALT?

0 Congress buys by 0 members and 0 insider buys are on file. The tables on this page list every one.

Did buying GALT after a disclosure beat the market?

No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.

Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.

Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.